

## PrecisION<sup>®</sup> hGABAA $\alpha$ 3/ $\beta$ 3/ $\gamma$ 2 Recombinant Stable Cell Line

**Catalog Number** CYL3068

**Lot Number**

See Vial

**Contents** 2 Vials, 2 x 10<sup>6</sup> to 4 x 10<sup>6</sup> in 1 mL

### Background Information

Gamma-aminobutyric acid (GABA)-gated ion channels are the major inhibitory neurotransmitter in the CNS, binding to fast-acting ionotropic GABA<sub>A</sub> receptors to cause inward flux of Cl<sup>-</sup> resulting in membrane hyperpolarization and thus reducing membrane excitability (Nutt et al., 2006). Excessive stimulation of these receptors can lead to sedation and ataxia whereas attenuation leads to arousal, insomnia and anxiety. Additional information can be found on page 2.

### Product Information

**Description** Recombinant HEK 293 cell line expressing the human GABAA  $\alpha$ 3,  $\beta$ 3 and  $\gamma$ 2 subunits

**Family** Chloride, Ligand-Gated

**Target** GABAA  $\alpha$ 3/ $\beta$ 3/ $\gamma$ 2

	Target Protein	Accession Number
1	GABAA $\alpha$ 3	NM_000808
2	GABAA $\beta$ 3	NM_000814
3	GABAA $\gamma$ 2	NM_000816
4	N/A	N/A

**Species** Human


**Host Cell Type** HEK 293

**Application** Electrophysiology assay (conventional and automated patch clamp platforms)

**Storage** Vials are to be stored in vapor phase of liquid nitrogen

### Functional Performance

HEK293 cells expressing hGABAA  $\alpha$ 3/ $\beta$ 3/ $\gamma$ 2 were characterized in terms of their pharmacological and biophysical properties using whole-cell patch clamp techniques.



**Electrophysiology Method** IonFlux

**Reference Agonist** GABAA

**Reference Antagonist** Bicuculline

**Antagonist IC<sub>50</sub> ( $\mu$ M)** 2.37

### Passage Stability

This cell line has been confirmed to be stable through at least 12 passages with no significant drop in assay window or change in pharmacology.

### Mycoplasma Testing

This lot was tested and found to be free of mycoplasma contamination. Data available upon request.

### Notes

Additional functional (pharmacological and electrophysiological) validation on multiple platforms is available upon request.

### Additional Ligand Information

**Control Compound** Bicuculline

**Vendor Name :** Tocris

**Vendor Catalog No.** 0130

### Additional Background Information

Since modulation of these receptors has such profound physiological effects they have become important drug targets for the treatment of many conditions e.g. anxiety, epilepsy, sleep disorders and for anesthesia (Rudolph and Mohler, 2006). GABA<sub>A</sub> receptors are pentameric structures typically consisting of  $\alpha$ ,  $\beta$  and  $\gamma$ 2 subunits in a stoichiometry of 2:2:1. The specific subunit composition is especially important since various combinations mediate different effects (Rudolph and Mohler, 2006). For example,  $\alpha$ 1-containing receptors, accounting for 60% of all GABA<sub>A</sub> receptors, mediate the sedative/hypnotic effects of benzodiazepines (BZPs) whereas the anxiolytic effects of these drugs are mediated by receptors containing  $\alpha$ 2 and  $\alpha$ 3 subunits (Korpi and Sinkkonen, 2006). Hence, developing selective allosteric modulators for these latter subunits should ultimately lead to anxiolytic drugs devoid of unwanted sedative effects.

**Ordering:** +1.510.979.1415 option 4 or e-mail [CustomerServiceDRX@eurofins.com](mailto:CustomerServiceDRX@eurofins.com)

**Technical support:** +1.510.979.1415 option 5 or e-mail [DRX\\_SupportUS@eurofinsUS.com](mailto:DRX_SupportUS@eurofinsUS.com)

**General product information:** [www.discoverx.com](http://www.discoverx.com)

### Limited Use License Agreement

**These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License.**

**Please visit [discoverx.com/license](http://discoverx.com/license) for a list of products that are governed by limited use label license terms and relevant patent and trademark information.**